BLND compared with MXCT: revenue, margins and what each company keeps, and the suppliers and customers both name

BLNDBlend Labs, Inc.

Mkt capRevenueRevenue

MXCTMaxcyte, Inc.

Mkt capRevenueRevenue

Compare

BLNDBlend Labs, Inc.

MXCTMaxcyte, Inc.

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Revenue flow

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Price

rebased to 0%

BLND, solidMXCT, dashed

Supply-chain overlap

Revenue flow

BLND: latest quarter is a loss; flow not drawable. MXCT: latest quarter is a loss; flow not drawable.Method ›

Supply-chain overlap

direct ties · both sidesSources ›

direct ties · both sides

Only BLND 0

None

Shared 0

No disclosed counterparties: BLND.

Only MXCT 5

TGTXTG Therapeuticscustomer

DTILPrecision BioSciencescustomer

—SeQure Dxunlistedsupplier

—Imugene (USA)unlistedcustomer

1 more · MXCT chain ›

Role chip = supplier or customer—= no ticker (unlisted)Source: SEC EDGAR

BLNDBlend Labs, Inc.

1.15· pre 1.15· delayed

Mkt cap$274.4MRevenue$34MQ2 FY26Revenue$124MFY25

MXCTMaxcyte, Inc.

1.44· pre 1.44· delayed

Pre-marketNov 3 '26delayed

Mkt cap$150.7MRevenue$7MQ2 FY26Revenue$33MFY25

Compare

Pre-marketNov 3 '26delayed

BLNDBlend Labs, Inc.

MXCTMaxcyte, Inc.

1.15pre 1.15delayed

Price

1.44pre 1.44delayed

$274.4M

Mkt cap

$150.7M

Q2 FY26$34M

Revenue

$7MQ2 FY26

FY25$124M

Revenue

$33MFY25

BLND1.15vsMXCT1.44Pre-marketNov 3 '26delayed